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Objectives: To investigate the association between systemic and local inﬂammation and incident and
progressive radiographic secondary osteoarthritis (OA) in interphalangeal joints (IPJs) over 3 years in
rheumatoid arthritis (RA) patients and the effect of tumor necrosis factor alpha (TNF-a) inhibitor
inﬂiximab on secondary OA in IPJs.
Methods: In the present observational longitudinal study baseline and 3-year hand X-rays of 416 recent-
onset RA patients were scored for osteophytes and erosions in IPJs, blinded for time, using Osteoarthritis
Research Society International atlas and Sharp-van der Heijde score. The associations between inﬂam-
matory factors and incident and progressive secondary OA in distal IPJs (DIPJs) and proximal IPJs (PIPJs)
and the effect of inﬂiximab compared to disease-modifying anti-rheumatic drug treatment on secondary
OA were analyzed by multivariable regression and generalised estimating equations analyses.
Results: Sixty-seven percent of the patients were female with, at baseline, a mean age of 54 years and OA
present in DIPJs and PIPJs in 37% and 13%. Three years later, new secondary OA in DIPJs and PIPJs was seen
in 11% and 10%, and progressive secondary OA in 36% and 35%. High erythrocyte sedimentation rate over
3 years and progressive erosive damage were risk factors for incident secondary OA in DIPJs, but not in
PIPJs. At joint level, progression of erosions was associated with both incident and progressive secondary
OA, only in DIPJs. Inﬂiximab treatment was associated with lower incident secondary OA in PIPJs [relative
risk 0.5 (95% conﬁdence interval 0.2, 1.0)], independent of decrease in inﬂammation.
Conclusion: Incident and progressive secondary OA in DIPJs over 3 years was associated with high
inﬂammatory activity in RA. Inﬂiximab treatment reduced incident secondary OA in PIPJs independent of
decrease in inﬂammation, suggesting that anti-TNF-a therapy might be effective against secondary hand
OA via other pathways than suppression of inﬂammation. Further studies in populations of primary hand
OA are necessary to determine the role of anti-TNF-a in treatment of primary hand OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) is a heterogenous group of conditions with
alterations in articular cartilage, bone and synovium1. A frequently
involved site is the hand where it leads to considerable loss in
function and quality of life2. At present, drug therapies used in OA
are limited to symptomatic treatment.to: M. Güler-Yüksel, Leiden
C, Leiden, The Netherlands.
el).
s Research Society International. PThe pathogenesis of OA is incompletely understood, but thought
to be multifactorial involving degenerative, biomechanical, meta-
bolic, hormonal and genetic factors3. Increasing evidence supports
the involvement of low-grade systemic and local inﬂammation in
the pathogenesis of OA. A two- to threefold increase in high
sensitive C-reactive protein levels is seen in OA patients4e7. High
resolution magnetic resonance imaging demonstrated subchondral
bone edema, synovial enhancement and bone erosions in inter-
phalangeal joints (IPJs) in the majority of OA patients8,9. Pro-
inﬂammatory cytokines are found in increased levels in synovial
ﬂuid of OA joints10e12, and heritable differences in cytokineublished by Elsevier Ltd. All rights reserved.
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OA13,14. Hence, inhibitors of cytokines might be considered as
potential candidates for disease-modifying therapy in OA15e17.
One of the pro-inﬂammatory cytokines involved in OA is tumor
necrosis factor alpha (TNF-a): increased TNF-a production and
increased p55 TNF-a receptor expression on chondrocytes imply
the intervention of TNF-a on joint destruction in OA18e23. It is
shown that TNF-a inhibitors are able to suppress nitric oxide
production in human cartilage24. Two pilot studies using anti-TNF-
a therapy in erosive hand OA reported some improvement in
clinical efﬁcacy measures, however the studies were small and
therefore inconclusive25,26.
In the present study we took advantage of the fact that in
patients with rheumatoid arthritis (RA) simultaneous development
and progression of secondary hand OA exists. In a trial in recent-
onset active RA patients who were treated with TNF-a inhibitors
and conventional disease-modifying anti-rheumatic drugs
(DMARDs) we investigated the associations between systemic and
local inﬂammatory factors and incident and progressive radio-
graphic secondary OA in IPJs over 3 years and the effect of treat-
ment with TNF-a inhibitor inﬂiximab on incident and progression
of secondary OA in IPJs in RA patients.Patients and methods
Patients
The present study is an exploratory observational longitudinal
study analyzing data from the BeSt study, an ongoing multicenter,
randomized clinical trial designed to compare the efﬁcacy of four
treatment strategies in recent-onset active RA patients, indepen-
dent of the conﬁrmatory strategy for any of the trial’s endpoints27.
In short, between April 2000 and August 2002, 508 RA patients
(American College of Rheumatology [ACR] 1987 revised criteria)
with symptom duration less than 2 years and active disease were
included. Inclusion and exclusion criteria were reported previously
in detail27. Rheumatologists participating in the Foundation for
Applied Rheumatology Research in 18 peripheral and two univer-
sity hospitals in the western part of the Netherlands designed and
conducted the BeSt study. The medical ethics committee at each
participating center approved the study protocol and all patients
gave written informed consent prior to participation in the study.Study design
According to the pharmacoprotocol of each treatment arm,
patients could be treated with the TNF-a inhibitor inﬂiximab in
combination with methotrexate 25 mg/week, either as initial
treatment or as delayed treatment after failing on at least three
previous DMARDs (‘inﬂiximab group’). Patients started with
inﬂiximab 3 mg/kg/8 weeks and in case of insufﬁcient response,
a disease activity score (DAS) in 44 joints >2.4, the dose was
increased step by step to 6, 7.5, and 10 mg/kg. If the DAS was 2.4
for at least six consecutive months, the dose of inﬂiximab was
reduced in reverse order to 3 mg/kg and stopped. Patients who did
not receive inﬂiximab during the study period (‘no inﬂiximab
group’) were treated with DMARDs (methotrexate, sulphasalazine,
leﬂunomide, hydrochloroquine) and prednisone, either as mono-
therapy or combination therapy. DAS, including the Ritchie artic-
ular index, the 44 swollen joint counts, the erythrocyte
sedimentation rate (ESR) and a general health assessment on
a visual analogue score, was measured three-monthly during the
follow-up period. In all patients, treatment adjustments, previously
described in detail, were based on aiming at DAS 2.427.Concomitant treatment with non-steroidal anti-inﬂammatory
drugs (NSAIDS) and anti-resorptives was permitted.
Radiographic assessment of secondary OA in IPJs
Radiographs of both hands were obtained at baseline and after 3
years. Osteophytes were scored in eight distal IPJs (DIPJs), eight
proximal IPJs (PIPJs) and two ﬁrst IPJs by one reader, blinded for
patient characteristics, treatment and chronological order, using
the Osteoarthritis Research Society International (OARSI) atlas
(scale 0e3 per joint)28. The scores of ﬁrst IPJs were merged with the
scores of PIPJs. Intra-reader variability for assessment of osteo-
phytes in DIPJs and PIPJs, depicted by the intra-class correlation
coefﬁcient (ICC) based on an at random selection of 30 pairs of hand
radiographs, was 0.91 and 0.90 with a smallest detectable change
(SDC) of 0.9 units for both joint groups.
OA in IPJs, DIPJs and PIPJs, at baseline was deﬁned as an osteo-
phyte score of at least 1 unit in IPJs, DIPJs and PIPJs, respectively. At
patient level, incident and progressive secondary OA in DIPJs and
PIPJs was deﬁned as an increase in total osteophyte score SDC
(¼0.9 units for DIPJs and PIPJs) over 3 years in absence and pres-
ence, respectively, of OA at baseline in DIPJs and PIPJs. At joint level,
incident and progressive secondary OA was deﬁned as an increase
in osteophyte score1 unit in one joint over 3 years in absence and
presence of OA in that joint at baseline.
Radiographic assessment of erosions in IPJs
Erosions were scored in 18 IPJs at baseline and after 3 years
using the Sharp-van der Heijde score (SHS) method (scale 0e5 per
joint) by the same reader in a second session, blinded for all data29.
According to the SHS method all erosions, whether typical of RA or
OA, are scored. The ICC for assessment of erosions in DIPJs and PIPJs
was 0.94 and 0.97 with SDCs of 1.3 and 1.1 units.
Erosive disease in DIPJs and PIPJs at baseline was deﬁned as an
erosion score 1 unit in DIPJs and PIPJs, respectively. At patient
level, progressive erosive damage in DIPJs and PIPJs was deﬁned as
an increase in erosion score SDC (1.3 units for DIPJs and 1.1 units
for PIPJs) over 3 years in DIPJs and PIPJs. At joint level, progressive
erosive damage was deﬁned as an increase in erosion score 1 unit
over 3 years.
Statistical analysis
Analyses were performed using SPSS, version 17 (SPSS, Chicago,
IL, USA).
To determine the independent demographic [input: age, gender
and body mass index (BMI)] and inﬂammation-related [input:
rheumatoid factor (RF), baseline ESR, area under the curve (AUC) of
ESR over 3 years, baseline erosion score and progressive erosion
score over 3 years 2 units] of incident and progressive secondary
OA in DIPJs and PIPJs, multivariable logistic regression analyses
were performed in which all variables were entered and adjusted
for anti-resorptive treatment [bisphosphonates, calcium and
vitamin D supplements and hormone replacement therapy (HRT)].
The association between osteophytes and erosions was further
explored at joint level by generalised estimating equations (GEE).
GEE is a regression technique that allows analyzing longitudinal or
clustered data while adjusting for within-patient correlation. GEE
requires an a prioriworking correlation structure in order to adjust
for the within-patient correlation. Based on the data an exchange-
able correlation structure was chosen here. Increase in osteophyte
score of 1 unit after 3 years was entered as dichotomous depen-
dent variable. Increase in erosion score of 1 unit after 3 years,
presence of OA at baseline and joint group (categorised in DIP and
Table I
Baseline demographic and disease related characteristics of the total study population and inﬂiximab and no inﬂiximab group
Total group n¼ 416 Inﬂiximab group n¼ 178 No inﬂiximab group n¼ 238 P-value
Demographic variables
Age, years, mean (SD) 54 (14) 52 (14) 56 (13) 0.001
Women, % 67 70 65 0.280
Postmenopausal, % (n¼ 279) 67 63 71 0.225
BMI, kg/m2, mean (SD) (n¼ 398) 26 (4) 26 (4) 26 (3) 0.720
Disease related variables
Inﬂammatory symptom duration, weeks,
median (IQR)
23 (14e53) 27 (15e56) 22 (13e42) 0.040
Positive IgM RF, % 65 68 63 0.345
HAQ score, 0e3, mean (SD) 1.4 (0.7) 1.4 (0.6) 1.3 (0.7) 0.469
ESR, mm/h, median (IQR) 37 (20e56) 34 (18e58) 37 (22e51) 0.987
Erosion score, mean (SD)
IPJs, 0e90 0.4 (1.9) 0.5 (2.4) 0.3 (1.3) 0.536*
DIPJs, 0e40 0.1 (0.9) 0.1 (0.7) 0.1 (1.0) 0.246*
PIPJs, 0e50 0.3 (1.4) 0.4 (2.0) 0.2 (0.8) 0.842*
1 erosion, %
IPJs 21 18 23 0.317
DIPJs 10 12 9 0.413
PIPJs 16 13 19 0.184
Osteophyte score, mean (SD)
IPJs, 0e54 1.7 (3.8) 1.2 (3.0) 2.0 (4.3) 0.006*
DIPJs, 0e24 1.3 (2.7) 0.9 (2.2) 1.6 (3.0) 0.009*
PIPJs, 0e30 0.4 (1.5) 0.3 (1.3) 0.5 (1.7) 0.533*
1 osteophyte, %
IPJs 38 30 44 0.004
DIPJs 37 29 42 0.010
PIPJs 13 12 14 0.535
HAQ: health assessment questionnaire.
* P-values derived by non-parametric tests.
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gender, BMI and anti-resorptive treatment and additionally for
erosion scores at baseline.
The effect of inﬂiximab treatment vs no inﬂiximab, thus
DMARD, treatment on incident and progressive secondary OA in
DIPJs and PIPJs were analyzed by multivariable logistic regression
analyses, adjusted for age, gender, BMI and anti-resorptive treat-
ment and variables differing between the treatment groups at
baseline and during study period. These analyses were repeated
while additionally adjustments for systemic and local inﬂamma-
tory factors to study whether the effect of inﬂiximab on secondary
OA could be explained by suppression of inﬂammation.
The odds ratios (OR) with 95% conﬁdence intervals (95% CI)
were transformed to relative risks (RR) and corresponding 95% CI
using the approximation formula described by Zhang and Yu as OR
for common outcomes in a closed cohort are not good approxi-
mations of RR30.Table II
Distribution of changes in osteophyte scores, in units, over 3 years in 416 patients
with absence and presence of OA in IPJs, DIPJs and PIPJs at baseline
3 2 1 0 1 2 3 4 5 6 7 8
No OA at baseline
All IPJs 0 0 0 226 13 7 5 0 3 1 1 1
DIPJs 0 0 0 233 14 9 4 2 1 0 0 0
PIPJs 0 0 0 327 20 6 6 2 0 0 0 1
OA at baseline
IPJs 2 10 19 52 33 19 13 4 1 2 0 4
DIPJs 1 7 16 74 27 17 6 1 0 2 1 1
PIPJs 2 3 9 21 11 6 2 0 0 0 0 0Results
Patient characteristics
In 416 of the 508 RA patients hand radiographs at baseline and
after 3 years were available and these patients were included in
the present study. Baseline characteristics of these patients are
demonstrated in Table I. The baseline characteristics were not
signiﬁcantly different between the patients in the present study
and the total study population (data not shown). 67% were
female, of whom 67% were postmenopausal at baseline. The mean
age was 54 years and 315 patients were over the age of 45. At
baseline, OA was present in IPJs in 39% of women and 36% of men.
OA occurred more often in DIPJs (37%) than in PIPJs (13%). Onlyeight patients (7.9%) below the age of 45 [mean standard devia-
tion (SD) 40 (3.9)] had OA in DIPJs and just one of these patients
had also OA in PIPJs. Erosive disease was present in IPJs in 21% of
the patients. Although erosions were more often seen in PIPJs
(16%), a considerable number of patients had also erosions in
DIPJs (10%). The patients who were treated with inﬂiximab were
signiﬁcantly younger, had longer inﬂammatory symptom duration
and less osteophytes in DIPJs at baseline. The ﬁnding of less
osteophytes in the inﬂiximab group was explained by the lower
age (data not shown).Incident and progressive secondary OA in IPJs
The distribution of changes in osteophyte scores in DIPJs and
PIPJs over 3 years is shown in Table II. Incident secondary OA
occurred in 31 patients (12%) in all IPJs, in 30 patients (11%) in DIPJs
and in 35 patients (10%) in PIPJs. Progressive secondary OA was
present in 76 patients (48%) in IPJs, in 55 patients (36%) in DIPJs and
in 19 patients (35%) in PIPJs.
Table III
Associations between demographic and inﬂammatory factors and incident and progressive secondary OA in DIPJs and PIPJs over 3 years derived by univariable logistic
regression analyses
DIPJs PIPJs
Incident secondary OA
n¼ 263
Progressive secondary OA
n¼ 153
Incident secondary OA
n¼ 362
Progressive secondary OA
n¼ 54
RR (95% CI) P-value RR (95% CI) P-value RR (95% CI) P-value RR (95% CI) P-value
Age <50 year 1 1 1 1
50e60 year 1.8 (1.1, 2.5) 0.023 1.0 (0.4, 2.0) 0.957 1.6 (0.8, 3.0) 0.162 0.2 (0.01, 2.1) 0.290
60 year 3.0 (1.5, 4.5) 0.003 1.1 (0.6, 1.4) 0.771 2.8 (1.8, 3.5) 0.000 1.2 (0.5, 1.5) 0.731
Female gender 1.4 (1.1, 1.5) 0.014 1.1 (0.8, 1.2) 0.573 1.1 (0.9, 1.3) 0.312 1.0 (0.6, 1.2) 0.817
BMI <25 kg/m2 1 1 1 1
BMI 25e30 kg/m2 0.9 (0.5, 1.5) 0.813 1.04 (0.7, 1.4) 0.858 0.7 (0.4, 1.3) 0.295 1.1 (0.4, 2.7) 0.898
BMI 30 kg/m2 1.3 (0.5, 2.9) 0.617 1.3 (0.5, 2.7) 0.619 1.1 (0.7, 1.4) 0.754 2.0 (0.3, 9.2) 0.488
Positive RF 1.1 (0.8, 1.3) 0.541 1.2 (0.9, 2.2) 0.260 0.9 (0.6, 1.1) 0.676 1.0 (0.6, 2.4) 0.983
Baseline ESR 30 mm/h 1.4 (1.04, 1.6) 0.031 0.9 (0.6, 1.2) 0.599 1.0 (0.7, 1.3) 0.978 1.4 (0.8, 1.8) 0.165
AUC ESR 0e3 year 30 mm/h 2.8 (1.5, 5.0) 0.003 1.4 (0.9, 2.0) 0.090 1.4 (0.8, 2.6) 0.255 1.1 (0.5, 1.9) 0.880
Baseline erosion score 1 unit 1.4 (0.4, 4.0) 0.599 1.2 (0.9, 1.9) 0.383 2.3 (0.98, 4.7) 0.059 1.2 (0.4, 3.0) 0.729
Delta erosion score 0e3 year 2 units 5.5 (1.3, 18.3) 0.023 1.7 (0.4, 7.2) 0.505 1.1 (0.3, 4.0) 0.923 5.5 (0.6, 22.3) 0.121
RR (95% CI): relative risk (95% CI).
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and inﬂammatory factors
The association between various demographic and inﬂamma-
tion-related factors and incident and progressive secondary OA
were analyzed by univariable logistic regression analyses (Table III).
To determine the independent risk factors of incident and
progressive secondary OA multivariable analyses were performed
(Table IV). Higher age was independently associated with incident
secondary OA in DIPJs and PIPJs and female gender only with
incident secondary OA in DIPJs. High AUC of ESR and progressive
erosion score over 3 years were associated with incident secondary
OA in DIPJs, however these associations were not statistically
signiﬁcant. Progression of erosions over 3 years was associated
with progressive secondary OA in PIPJs but not independently.
None of the other demographic and inﬂammation-related factors
were related to progressive secondary OA in DIPJs and PIPJs.
Table V summarizes the results of the GEE analyses. The pres-
ence of an osteophyte in an interphalangeal hand joint at baseline
increased the chance of having an increase in the osteophyte score
in the same joint during the study period with a RR (95% CI) of 1.6
(1.2, 1.9) and increase of osteophyte score was more often seen in
DIPJs than in PIPJs with a RR (95% CI) of 1.7 (1.1, 1.5). Progressive
erosion score in an interphalangeal hand joint was associated with
an increase in the osteophyte score in the same joint with a RR (95%
CI) of 2.5 (0.9, 6.4). Interaction and post hoc analyses showed that
progressive erosive damage in a single joint was signiﬁcantly
associated with both incident and progressive OA only in DIPJs
(P¼ 0.036 and 0.045, respectively), not in PIPJs.Table IV
Independent associations between demographic and inﬂammatory factors and incide
multivariable logistic regression analyses
DIPJs
Incident secondary OA
n¼ 263
Progressive s
n¼ 153
RR (95% CI) P-value RR (95% CI)
Age <50 year 1
50e60 year 1.7 (0.9, 2.5) 0.073 e
60 year 3.5 (1.8, 5.2) 0.002 e
Female gender 1.5 (1.2, 1.6) 0.003 e
AUC ESR 0e3 year 30 mm/h 1.6 (0.9, 2.1) 0.081 e
Delta erosion score 0e3 year 2 units 5.1 (0.9, 15.6) 0.068 e
Following variables were entered in the multivariable analyses: age, gender, BMI, prese
erosion score 0e3 year, adjusted for anti-resorptive treatment during study period.Effect of inﬂiximab on incident and progressive secondary OA in IPJs
During the study period 178 (43%) patients were treated with
inﬂiximab. The median interquartile range (IQR) cumulative
inﬂiximab dose was 40 (24e61) mg/kg during a median (IQR)
period of 13 (9e21) months. The patients from the ‘no inﬂiximab
group’ were treated with conventional DMARDs: 60% with
combination therapy, mostly methotrexate and sulphasalazine
with prednisone and/or hydrochloroquine. After 3 years, 58% still
received monotherapy (60% methotrexate, 31% sulphasalazine
monotherapy, 9% other), and 13% had discontinued all treatment
due to clinical remission. Patients in the inﬂiximab group received
less bisphosphonates (12% vs 22%, P¼ 0.013) due to lower corti-
costeroid use, but more HRT (21% vs 11%, P¼ 0.005) due to more
perimenopausal women. There were no signiﬁcant differences in
the use of NSAIDS and speciﬁc cyclooxygenase 2 (COX 2) inhibitors
between the treatment groups (data not shown). None of these
treatments had effect on incident or progressive secondary OA over
3 years (data not shown).
Treatment with inﬂiximab was associated with less incident
secondary OA in PIPJs, however not statistically signiﬁcant [6% vs
13%, P¼ 0.059, Table VI, Fig. 1(A)]. Five patients treated with
inﬂiximab (24%) had progressive secondary OA in PIPJs vs 14 (42%)
of the patients not treated with inﬂiximab [P¼ 0.163, Table VI, Fig. 1
(B)]. In multivariable analyses, adjusted for age, gender, meno-
pausal status, BMI, inﬂammatory symptom duration, OA at baseline
and the use of anti-resorptive treatment during the study period,
treatment with inﬂiximab showed a trend towards less incident
secondary OA in PIPJs with a RR (95% CI) of 0.5 (0.2, 1.1) (P¼ 0.087,nt and progressive secondary OA in DIP and PIP joints over 3 years derived by
PIPJs
econdary OA Incident secondary OA
n¼ 362
Progressive secondary OA
n¼ 54
P-value RR (95% CI) P-value RR (95% CI) P-value
1
e 1.6 (0.8, 2.4) 0.191 e e
e 2.9 (1.8, 3.6) 0.001 e e
e e e e e
e e e e e
e e e e e
nce of RF, baseline ESR, AUC ESR 0e3 year, baseline erosion score and progressive
Table V
Associations between presence of hand OA at baseline, distribution over the joints
(DIPJs and PIPJs) and progressive erosive damage and changes in osteophyte scores
over 3 years at joint level in IPJs derived by GEE
Variables Delta osteophyte score 1 unit per
joint
RR (95% CI) Overall P-value
Presence hand OA at baseline 1.6 (1.2, 1.9) 0.003
DIPJs vs PIPJs 1.7 (1.1, 1.5) 0.006
Delta erosion score 1 unit per joint 2.5 (0.9, 6.4) 0.078
All data are adjusted for age, gender, BMI and anti-resorptive treatment and delta
erosion score 1 unit is additionally adjusted for erosive damage at baseline.
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inﬂammatory factors over 3 years did not change the association
between inﬂiximab treatment and incident secondary OA in PIPJs,
which suggests that the effect of inﬂiximab on incident secondary
OA in PIPJs is independent of suppression of inﬂammatory activity
over 3 years (Table VI). After adjustment for inﬂammatory activity
during 3 years, the effect of inﬂiximab on incident secondary OA in
DIPJs was also getting more substantial, but not signiﬁcant, with
a RR (95% CI) of 0.6 (0.2, 1.3) compared to 1.0 (0.5, 1.9) in the
unadjusted analysis. Inﬂiximab did not have an effect on progres-
sive secondary OA in DIPJs and PIPJs.
Discussion
The present study showed, by an alternative approach evalu-
ating secondary OA outcome in patients with RA, two important
ﬁndings: (1) there is a link between inﬂammation, measured by
high ESR and progressive erosive damage over 3 years, and incident
and progressive secondary OA in DIPJs but not in PIPJs; and (2)
there is a clear trend towards an inhibitory effect of treatment with
inﬂiximab on incident secondary OA in PIPJs, not in DIPJs, inde-
pendent of the effect of inﬂiximab on inﬂammatory activity during
3 years.
There has been increasing evidence that both low-grade
systemic and local inﬂammation are playing a role in the
pathogenesis of primary OA4e9. We found that high systemic
and local inﬂammation during 3 years, measured by high AUC
of ESR (at patient level) and progressive erosive damage (at
joint level), were signiﬁcantly associated with incident and/or
progressive secondary OA in DIPJs in RA patients, suggesting
that systemic inﬂammation might play a role in the develop-
ment of secondary hand OA. The differences in association
between inﬂammation and the development of secondary OA inTable VI
Incident and progressive secondary OA in DIPJs and PIPJs over 3 years between the inﬂ
multivariable logistic regression analyses
Chi-square analyses DIPJs
Incident secondary OA Progr
No. patients/
total no. (%)
P-value No. pa
total n
Inﬂiximab group 14/125 (11) 0.920 20/5
No inﬂiximab group 16/138 (12) 35/10
Logistis regression analyses RR (95% CI) P-value RR (9
Inﬂiximab group, unadjusted 1.0 (0.5, 1.9) 0.920 1.1 (0
Inﬂiximab group, adjusted for demographics* 0.8 (0.4, 1.7) 0.578 1.2 (0
Inﬂiximab group, adjusted for demographics
and cumulative inﬂammatory activityy
0.6 (0.2, 1.3) 0.182 1.1 (0
* Adjusted for age, gender, BMI and anti-resorptive treatment.
y Adjusted for age, gender, BMI, and anti-resorptive treatment, presence of RF, baseline
3 years.DIPJs and PIPJs in RA patients could be due to differences in the
level of inﬂammation at the different joint levels in RA patients
and in differences in the role of inﬂammation with regard to the
pathophysiological mechanisms of secondary OA between DIPJs
and PIPJs.
Previous studies showed that joint tissues in primary OA are
the site of active production of TNF-a enhancing joint
destruction18e23. Two pilot studies and one case report showed
positive results of anti-TNF-a treatment in primary OA
patients25,26,31. The ﬁrst pilot study was an open-label study and
showed in 12 patients with inﬂammatory erosive hand OA treated
with adalimumab 40 mg/2 weeks for 3 months signiﬁcant
improvement in the number of swollen joints and similar trends
in other outcome measures25. The second pilot study was a 1-year
placebo-controlled double-blind study and showed in 10 female
patients with erosive hand OA treated with monthly intra-artic-
ular injections of inﬂiximab 0.1 mg/ml or physiological saline for 1
year signiﬁcant improvement in pain scores and non-signiﬁcant
reduction of radiographic score in IPJs in the inﬂiximab group26.
However, these studies were small and therefore inconclusive. We
found a clear trend towards an inhibitory effect of inﬂiximab on
incident secondary OA: inﬂiximab treatment resulted in a twofold
decrease in incident secondary OA in PIPJs in RA patients, inde-
pendent of the effect of inﬂiximab on suppression of inﬂamma-
tion. This suggests that treatment with TNF-a inhibitors might be
effective against development of secondary OA, however not by
inﬂammatory pathways, but by other bone linked pathways. This
corresponds with the absence of an association between inﬂam-
mation and secondary OA in PIPJs and the observed increasing
trend towards a more protective effect of inﬂiximab against
incident secondary OA in DIPJs after adjusted for cumulative
systemic and local inﬂammatory activity during 3 years. Osteo-
phytes are thought to be formed by mesenchymal stem cells
present in the periosteum or synovial lining undergoing chon-
drogenesis, followed by endochondral ossiﬁcation and deposition
of bone32. The process is not fully understood, but key factors
appear to be transforming growth factor beta and insuline-like
growth factor-I32. We speculate that TNF-a might also play a role
in the process of osteophyte formation, since inhibition of TNF-
a appears to suppress it. Therefore we think that our data on
secondary hand OA might also be relevant for primary hand OA,
suggesting that treatment with TNF-a inhibitors might reduce the
development or progression of primary hand OA and this might
be possibly via other mechanisms than suppression of inﬂam-
mation. Large randomized, placebo-controlled, clinical trials in
primary hand OA are needed to conﬁrm this.iximab and ‘no inﬂiximab group’ derived by chi-square tests and univariable and
PIPJs
essive secondary OA Incident secondary OA Progressive secondary OA
tients/
o. (%)
P-value No. patients/
total no. (%)
P-value No. patients/
total no. (%)
P-value
3 (38) 0.737 9/157 (6) 0.059 5/21 (24) 0.163
0 (35) 26/205 (13) 14/33 (42)
5% CI) P-value RR (95% CI) P-value RR (95% CI) P-value
.7, 1.7) 0.737 0.5 (0.2, 0.9) 0.027 0.6 (0.2, 1.3) 0.163
.7, 1.8) 0.490 0.5 (0.2, 1.1) 0.087 0.6 (0.2, 1.5) 0.477
.6, 1.7) 0.682 0.5 (0.2, 1.0) 0.059 0.5 (0.1, 1.6) 0.332
ESR, AUC ESR 0e3 years, baseline erosion score and progressive erosion score over
Fig. 1. Incident (A) and progressive (B) secondary OA in PIPJs over 3 years in the
inﬂiximab and no inﬂiximab group. Incident secondary OA is deﬁned as an increase in
osteophyte score 1 unit in absence of OA at baseline, thus 26/205¼12.7% incident
secondary OA in PIPJs in the no inﬂiximab group compared to 9/157¼ 5.7% in the
inﬂiximab group. Progressive secondary OA is deﬁned as an increase in osteophyte
score 1 unit in presence of OA at baseline, thus 14/33¼ 42.4% progressive secondary
OA in PIPJs in the no inﬂiximab group compared to 5/21¼23.8% in the inﬂiximab
group.
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progression of secondary OA is studied in a RA cohort. First, in this
setting the evaluation of two diseases in a single joint might be less
reliable. Second, the value of radiographic evaluation by the pres-
ence of osteophytes, in stead of the much wider used joint space
narrowing, might be argued, however the evaluation of cartilage
degradation was not preferred in this study due to high occurrence
in both diseases. The focus on osteophytes might introduce the
possibility of underestimation of incident and progressive
secondary OA, however any possible misclassiﬁcation of OA is non-
differential with regard to treatment because the radiographic
changes were assessed blinded for the treatment group. Further-
more changes in bone and cartilage seem to be tightly coupled in
OA33, emphasized by the protective effect of alendronate on both
cartilage degradation and osteophyte formation in a rat model34.
Third, a minority of the patients had OA at baseline and a 3-year
follow-up period is relatively short for OA processes, hence the
numbers of patients who had incident and progressive secondary
OA in IPJs over 3 years were rather small, especially progressivesecondary OA in PIPJs was only seen in 19 patients. A longer follow-
up period might reveal more incident and progressive secondary
OA and therefore add power to ﬁnd associations between inﬂam-
mation and TNF-a inhibition and incident and progressive
secondary OA.
In conclusion, our study showed that high systemic and local
inﬂammation is linked to incident and progressive secondary OA in
DIPJs over 3 years in recent-onset active RA patients. Treatment
with a TNF-a inhibitor might decrease incident secondary OA in
PIPJs, independent of the suppression of inﬂammation. The value of
anti-TNF-a in treatment of primary hand OA is still unknown and
needs further research.
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